AT regimen

DRUG2 trials

Sponsors

Sichuan Provincial People's Hospital

Conditions

HER2-negative Breast CancerTriple-negative Breast Cancer

Phase 2

AT Versus TP as Neoadjuvant Chemotherapy in Patients With HER2-negative Early Breast Cancer

Sichuan Provincial People's HospitalHER2-negative Breast Cancer

Start: 2020-08-31End: 2021-08-31Target: 100Updated: 2020-08-05

A Phase Ⅱ Study of Anlotinib Combined With Tislelizumab and AT in the Neoadjuvant Treatment of Triple-negative Breast Cancer

RecruitingNCT04914390

Sichuan Provincial People's HospitalTriple-negative Breast Cancer

Start: 2023-09-15End: 2025-09-30Target: 32Updated: 2024-01-22

Related Papers

The preliminary efficacy and safety results of neoadjuvant phase II study of anlotinib plus tislelizumab combined with chemotherapy in triple-negative breast cancer.

Journal of Clinical Oncology2025-05-28

Anlotinib plus tislelizumab combined with chemotherapy as neoadjuvant treatment in triple-negative breast cancer: A prospective, single-arm, open-label phase II study.

Journal of Clinical Oncology2022-06-01